About this trial
This study examines how glucagon works to regulate glucose metabolism, based on new findings that suggest glucagon signaling in the liver has more than one role, and that these multiple roles can be opposing in nature. Understanding this biology provides an opportunity to develop new generations of glucagon-based drugs that target specific pathways, making them more effective at controlling blood glucose.
Participants will complete paired, 5-hour hyperinsulinemic glucose clamp visits in which they receive either glucagon or saline infusions while blood glucose is maintained and frequent blood samples are collected. The primary focus is whether coordinated glucagon and insulin signaling enhances hepatic insulin sensitivity.
Eligibility criteria
Qualifiers
Healthy adults age 18-45 years
Body Mass Index (BMI) < 27.0 kg/m²
Fasting plasma glucose ≤ 95 mg/dL or HbA1c ≤ 5.8% as measured at screening visit
Disqualifiers
Active medical disease: e.g. active infectious, inflammatory, neurodegenerative or mental health disorders
No personal history of diabetes or pancreatitis
No personal history of cardiac, gastrointestinal, renal or liver disease
No history of diabetes among any first-degree family members
Trial design
Treatments tested in this trial
- Glucagon
- Saline (placebo)
Treatment groups
Sponsors and collaborators
Duke University
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Collaborator